Craft
  • Home
  •  / Lexicon Pharmaceuticals
Lexicon Pharmaceuticals

Lexicon Pharmaceuticals

Phase I Trials Products

1

FY, 2016

Revenue

$298 K

FY, 2019

Market Capitalization

$326.1 M

2022-11-21

Lexicon Pharmaceuticals Summary

Company summary

Overview
Lexicon Pharmaceuticals is a fully integrated biopharmaceutical company that is applying a unique approach to gene science based on Nobel Prize-winning technology to discover and develop precise medicines for people with serious, chronic conditions.  All of the Company's drug candidates are new molecular entities discovered internally by its dedicated drug discovery teams and designed to affect particular points on a genetically-defined pathway that can be used to fight a disease process. Lexicon Pharmaceuticals has advanced new therapies across a wide spectrum of human disease, from conditions affecting millions of people, such as diabetes, to carcinoid syndrome.
Type
Public
Status
Active
Founded
1995
HQ
The Woodlands, TX, US | view all locations
Website
http://www.lexpharma.com
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key people

  • Raymond Debbane
  • Jeffrey L. Wade

    Jeffrey L. Wade, Executive Vice President, Corporate and Administrative Affairs and Chief Financial Officer

  • James F. Tessmer

    James F. Tessmer, Vice President of Finance and Accounting

  • Alan J. Main

    Alan J. Main, Executive Vice President, Innovation and Chemical Sciences

Operating MetricsView all

Phase I Trials Products

1

FY, 2016

Products

1

FY, 2016

Pre-Clinical Phase Products

1

FY, 2016

LocationsView all

29 locations detected

  • The Woodlands, TX HQ

    United States

    2445 Technology Forest Blvd 11th Floor

  • Atlanta, GA

    United States

    Atlanta, GA, USA

  • Bernards, NJ

    United States

    110 Allen Rd

  • Birmingham, AL

    United States

    Birmingham, AL, USA

  • Boston, MA

    United States

    Boston, MA, USA

  • Charlotte, NC

    United States

    Charlotte, NC, USA

and 23 others

Lexicon Pharmaceuticals Financials

Summary financials

Net income (Q3, 2022)
($23.4M)
Cash (Q3, 2022)
$18.8M
EBIT (Q3, 2022)
($23.1M)
Enterprise value
$336.5M

Footer menu